Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral ProgramsGlobeNewsWire • 05/14/20
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of ActionGlobeNewsWire • 04/22/20
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D.GlobeNewsWire • 04/20/20
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020GlobeNewsWire • 03/30/20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 03/11/20
Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 03/09/20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 02/28/20
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 02/27/20
Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of AntiviralsGlobeNewsWire • 02/13/20
Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor ConferenceGlobeNewsWire • 02/11/20
COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERINGGlobeNewsWire • 02/03/20
Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/19
Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCVGlobeNewsWire • 11/11/19
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCKGlobeNewsWire • 10/30/19
Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver MeetingGlobeNewsWire • 10/30/19